Last Updated : November 27, 2014
Details
FilesGeneric Name:
Alemtuzumab
Project Status:
Complete
Therapeutic Area:
Multiple sclerosis, relapsing-remitting
Manufacturer:
Genzyme Canada, a Division of Sanofi-Aventis Canada Inc.
Call for patient/clinician input open:
Brand Name:
Lemtrada
Project Line:
Reimbursement Review
Project Number:
SR0405-000
Call for patient/clinician input closed:
NOC Status at Filing:
Post NOC
Submission Type:
Initial
Indications:
Multiple Sclerosis, relapsing-remitting
Recommendation Type:
List with criteria/condition
Final Recommendation:
Files
Last Updated : November 27, 2014